Retina

Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads.

The VAN-2401 phase 1 clinical trial will evaluate the use of KH658 for the treatment of wet AMD.

Topcon Healthcare launches IDHea, an innovative platform enhancing AI research and ocular data access to improve clinical outcomes in healthcare.

The trial will assess allogeneic retinal pigment epithelium cells in the treatment of geographic atrophy.

In this Q&A, Luke Lindsell, OD, MD, shares his insights on emerging therapies in retina, the evolving role of optometrists in retinal disease management, and the importance of comanagement in patient care.

Opus Genetics reveals promising 1-year results from OPGx-LCA5 gene therapy, showing sustained vision improvements in adults with LCA5 retinal degeneration.

New research reveals subretinal drusenoid deposits as potential indicators of serious heart disease, highlighting the need for ophthalmologists to screen patients effectively.

Researchers stratified a dataset of more than 100 patients in an emergency department to see which patients may be indicated for retinal artery occlusions.

At the ARVO 2025 meeting in Salt Lake City, Utah, Cameron Cummings presented a poster on how retinal microvascular imaging metrics may show sex-specific biomarkers for Parkinson's disease.

New research links genetic risk for schizophrenia to retinal thinning, suggesting early indicators of the disorder may be found in retinal morphology.

The OcuMet Beacon is a proprietary, noninvasive tool for assessing retinal health. The company said it will be available on the US market for use in clinics and health care institutions.

4D-150 is a potential backbone therapy that is designed to provide multiyear sustained delivery of anti-VEGF (aflibercept and anti–VEGF-C) to be targeted to the retina with a single, well-tolerated intravitreal injection.

A novel vitrectomy device shows promising safety and efficacy in the targeted removal of symptomatic vitreous opacities in pseudophakic eyes

Researchers evaluate key measures for tracking disease progression in Usher syndrome type 2–related retinal degeneration

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City, Utah.

Researchers unveil a groundbreaking method to stimulate retinal M cells, creating a new color, "olo," beyond human vision's natural limits.

A new event called SightLine and a series on adoption, implementation, integration (AII) draw the attention of ophthalmic administrators.

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia.”

Celebrating a half-century of progress with Ophthalmology Times.

The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion and broadening the dosing schedule to include every-4-week dosing across approved indications.

In their study, 16 ophthalmologists, including attending physicians and residents with levels of experience ranging from 1 to 9 years, were included.